Riyadh, October 6, 2024 — The CEO of the Saudi Food and Drug Authority (SFDA), Dr. Hisham bin Saad Al-Jadhey, led the Kingdom of Saudi Arabia’s delegation to the 2024 Annual Meeting of the International Society of Pharmacovigilance (ISoP), held in Montreal, Canada, from October 1 to 5, according to the Saudi Press Agency (SPA). The participation underscores the SFDA’s commitment to advancing global pharmacovigilance and drug safety through international collaboration.
Context and Background
The ISoP Annual Meeting is a premier global forum that brings together experts in clinical and scientific aspects of drug safety. This year’s event attracted over 1,000 members from 108 countries, highlighting its significance as a platform for sharing knowledge and best practices. The SFDA’s active role reflects Saudi Arabia’s growing influence in global health governance and its dedication to protecting public health.
Key Details
Dr. Al-Jadhey participated in a high-level dialogue session titled “The Status of Pharmacovigilance in the Digital Age Around the World,” alongside officials from the Canadian Ministry of Health, the U.S. Food and Drug Administration, the World Health Organization, the European Medicines Agency, and the Swiss Agency for Therapeutic Products. In his remarks, he highlighted the SFDA’s pioneering initiatives in leveraging digital solutions to enhance drug safety.
He emphasized the authority’s efforts in advancing digital technologies, citing projects such as the Pharmacovigilance Electronic Reporting Service, which tracks adverse drug reactions (ADRs), and the e-learning platform for risk minimization measures (aRMMS). These initiatives underscore Saudi Arabia’s leadership in integrating digital innovations within drug safety.
On the sidelines of the conference, Dr. Al-Jadhey held meetings with officials from the Canadian Ministry of Health and representatives of several Canadian companies specializing in drug safety, vaccines, and biotechnology. Discussions focused on potential collaboration in research, laboratory advancements, knowledge exchange, and training programs.
Additionally, SFDA staff presented 10 scientific papers on drug safety at the research exhibition accompanying the ISoP annual meeting, further demonstrating the Kingdom’s expertise in the field.
Implications and Impact
The SFDA’s active participation in the ISoP annual meeting and its bilateral discussions with Canadian counterparts signal Saudi Arabia’s commitment to international cooperation in health security. By sharing its digital innovations and learning from global partners, the Kingdom contributes to setting international standards for drug safety. This engagement also opens avenues for partnerships that can enhance Saudi Arabia’s pharmaceutical and biotechnology sectors, aligning with broader economic diversification goals.
Vision 2030 Alignment
This participation aligns with Saudi Vision 2030’s objectives to strengthen the Kingdom’s healthcare system and position it as a leader in innovation. By fostering global collaborations and integrating digital solutions, the SFDA supports the vision’s aim to enhance the quality of life for citizens and residents while contributing to a safer, more interconnected world.
20 Questions
Q1. What event did Dr. Hisham bin Saad Al-Jadhey lead the Saudi delegation to?
A1. Dr. Al-Jadhey led the Saudi delegation to the 2024 Annual Meeting of the International Society of Pharmacovigilance (ISoP) in Montreal, Canada.
Q2. When and where was the ISoP Annual Meeting held?
A2. The meeting was held from October 1 to 5 in Montreal, Canada.
Q3. What is the primary focus of the ISoP Annual Meeting?
A3. The meeting focuses on clinical and scientific aspects of drug safety, bringing together experts from around the world.
Q4. How many countries were represented at the ISoP Annual Meeting?
A4. Over 1,000 members from 108 countries attended the event.
Q5. What was the title of the dialogue session Dr. Al-Jadhey participated in?
A5. The session was titled “The Status of Pharmacovigilance in the Digital Age Around the World.”
Q6. Which international organizations were represented in the dialogue session?
A6. Officials from the Canadian Ministry of Health, the U.S. Food and Drug Administration, the World Health Organization, the European Medicines Agency, and the Swiss Agency for Therapeutic Products participated.
Q7. What digital initiatives did Dr. Al-Jadhey highlight?
A7. He highlighted the Pharmacovigilance Electronic Reporting Service and the e-learning platform for risk minimization measures (aRMMS).
Q8. What is the purpose of the Pharmacovigilance Electronic Reporting Service?
A8. It tracks adverse drug reactions (ADRs) to enhance drug safety monitoring.
Q9. What is aRMMS?
A9. aRMMS is an e-learning platform for risk minimization measures, designed to educate on drug safety.
Q10. With whom did Dr. Al-Jadhey hold sideline meetings?
A10. He met with officials from the Canadian Ministry of Health and representatives of Canadian companies specializing in drug safety, vaccines, and biotechnology.
Q11. What topics were discussed in the sideline meetings?
A11. Discussions focused on potential collaboration in research, laboratory advancements, knowledge exchange, and training programs.
Q12. How many scientific papers did SFDA staff present?
A12. SFDA staff presented 10 scientific papers on drug safety at the research exhibition.
Q13. What does the SFDA’s participation demonstrate?
A13. It demonstrates the SFDA’s commitment to global pharmacovigilance and sharing expertise in drug safety.
Q14. How does this participation align with Saudi Vision 2030?
A14. It aligns with Vision 2030 by strengthening healthcare and fostering innovation through global collaboration.
Q15. What are the potential benefits of the SFDA’s engagement with Canadian entities?
A15. It opens avenues for partnerships that can enhance Saudi Arabia’s pharmaceutical and biotechnology sectors.
Q16. What is the significance of the ISoP Annual Meeting for global drug safety?
A16. It serves as a platform for experts to share knowledge and best practices, advancing international drug safety standards.
Q17. How does the SFDA contribute to global drug safety efforts?
A17. The SFDA contributes by sharing its digital innovations, presenting research, and engaging in international collaborations.
Q18. What role does digital innovation play in the SFDA’s strategy?
A18. Digital innovation is central to enhancing drug safety monitoring and risk minimization, as shown by its electronic reporting and e-learning platforms.
Q19. Who is Dr. Hisham bin Saad Al-Jadhey?
A19. Dr. Al-Jadhey is the CEO of the Saudi Food and Drug Authority (SFDA).
Q20. What does the SFDA’s participation mean for Saudi Arabia’s global health leadership?
A20. It reinforces Saudi Arabia’s role as a proactive leader in global health, contributing to and learning from international best practices.
Reader Feedback
We value your thoughts. Please share your feedback on this article.
Your feedback helps us improve our coverage.